Microglia and Autism Spectrum Disorder: Overview of Current Evidence and Novel Immunomodulatory Treatment Options.
10.9758/cpn.2018.16.3.246
- Author:
Jung Won KIM
1
;
Ji Yeon HONG
;
Seung Min BAE
Author Information
1. Department of Psychiatry and Behavioral Neurobiology, University of Alabama at Birmingham, Birmingham, AL, USA.
- Publication Type:Review
- Keywords:
Autism spectrum disorder;
Maternal immune activation;
Microglia;
Immunomodulatory therapy
- MeSH:
Autism Spectrum Disorder*;
Autistic Disorder*;
Brain;
Humans;
Immunomodulation;
Microglia*;
Minocycline;
Suramin;
Vitamin D
- From:Clinical Psychopharmacology and Neuroscience
2018;16(3):246-252
- CountryRepublic of Korea
- Language:English
-
Abstract:
Autism spectrum disorder is a rapidly increasing heterogeneous neurodevelopmental syndrome, remarked by persistent deficit in social communication, and restricted, repetitive patterns of behavior and interest. Lately, maternal immune activation and micgroglial dysfunction in the developing brain have been gaining mounting evidence and leading to studies of various novel agents as potential treatment options. A few immunomodulatory treatment options—luteolin, minocycline, suramin, vitamin D, gut microbiota—are discussed in the current article, regarding the current understanding of their mechanisms and evidence for potential clinical use. More studies are warranted to understand their exact mechanisms of action and to verify efficacy and safety in human subjects.
